Chromosome condensation is essential for proper segregation of duplicated sister chromatids in mitosis. Mammalian erythroid maturation is also associated with gradual nuclear condensation. However, few proteins that are directly involved in chromosome condensation during erythropoiesis have been identified. In this report, we show that MTB (more than blood), which was initially isolated in a yeast two-hybrid screen for proteins that interact with the basic helix-loop-helix (bHLH) protein stem cell leukemia (SCL), and later identified as the murine homolog of the condensin II subunit CAP-G2, participates in erythroid cell development. MTB interacts with SCL and another hematopoietic bHLH protein, E12, and is recruited to the nucleus by SCL and E12. In addition, MTB can repress SCL/E12-mediated transcriptional activation. Consistent with the model that MTB may function together with SCL/E12 heterodimer during erythroid cell development, MTB is highly expressed in the erythroid lineage and is upregulated upon erythroid differentiation. Moreover, overexpression of MTB promotes the terminal differentiation of the murine erythroleukemia erythroid cell line. Together, these findings demonstrate that the condensin II subunit MTB/mCAP-G2 plays a novel function during erythropoiesis and suggest that key hematopoietic transcription factors such as SCL and E12 may regulate the terminal differentiation of hematopoietic cells through the interaction with condensin complexes.
Introduction
During mitosis, the duplicated genomic DNA has to be structurally reorganized into condensed chromosomes for the faithful segregation of sister chromatids. Two related protein complexes, condensin I and condensin II, are involved in this process. Each condensin complex is composed of five subunits: two structural maintenance of chromosome (SMC) proteins (SMC2/CAP-E and SMC4/CAP-C) shared by the two complexes, and three non-SMC proteins (CAP-D2, CAP-G and CAP-H in condensin I versus CAP-D3, CAP-G2 and CAP-H2 in condensin II). Structural maintenance of chromosome2 and 4 are chromosomal ATPases, whereas the non-SMC proteins likely modulate the activity of the SMC heterodimer or may regulate the spatial and temporal distribution of each complex. [1] [2] [3] Recent studies have provided evidence that condensin complexes and individual condensin subunits contribute to nonmitotic processes such as X-chromosome dosage compensation in Caenorhabditis elegans 4,5 epigenetic control of homeotic gene expression in Drosophila 6 and DNA repair in Saccharomyces pombe.
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In addition to mitosis, chromosome condensation is also a common phenomenon during terminal differentiation of many hematopoietic cells, including erythroid cells, megakaryocytes and lymphocytes. As these cells become progressively more mature, nuclear chromatin becomes increasingly condensed and transcription in general is gradually repressed. Although many lineage-specific transcription factors have been well characterized, only a few proteins involved in chromatin structure during hematopoiesis have been identified. For example, Grigoryev et al. 8 showed that the nonhistone nuclear protein mature erythrocyte nuclear termination stage-specific protein (MENT), which associates with repressed chromatin in mature chicken erythrocytes, promotes chromatin condensation and nuclear collapse at the terminal stage of avian erythropoiesis. 8, 9 However, no MENT homolog or MENT-like proteins have been identified in mammalian erythrocytes. Therefore, proteins involved in chromatin condensation during mammalian erythropoiesis remain to be identified.
In this study, we characterize the function of MTB (more than blood), a murine condensin II subunit, during erythroid differentiation. MTB was initially identified by our group as an stem cell leukemia (SCL)-interacting protein in a yeast twohybrid screen. 10 Stem cell leukemia, a basic helix-loop-helix (bHLH) transcription factor critical for multiple stages of hematopoiesis, is essential for survival or specification of embryonic hematopoietic stem cells (for a review, see Lecuyer and Hoang 11 ). Stem cell leukemia also plays an important role in promoting the terminal differentiation of erythroid cells, although it is not essential for adult hematopoietic stem cell function. 12 As a class II bHLH protein, SCL forms heterodimers with E-proteins, including the E2A proteins E12 and E47. The heterodimer recognizes E-box motifs in DNA and can act as a transcriptional activator in mammalian cells, likely through the ability of SCL to recruit the general transcriptional coactivator p300. 11 On the other hand, SCL can also associate with the corepressor mSin3A in proliferating erythroid cells and repress transcription by recruitment of histone deacetylase. 13 More recently, it has been shown that SCL/E2A interacts with ETO-2 to form a repression complex in proerythroblasts. 14, 15 Thus, SCL appears to function both as an activator and repressor, dependent on its cellular context. MTB is the murine homolog of FLJ20311, which has been identified as one of the condensin II complex subunits hCAP-G2. 1 Here, we show that MTB interacts with SCL and E12 in mammalian cells and represses E-box-mediated transcriptional activation. In addition, MTB is highly expressed in erythroid cells, and is upregulated upon erythroid cell differentiation. Overexpression of MTB in murine erythroleukemia (MEL) cells promotes their erythroid differentiation, which is accompanied by increased downregulation of an SCL target gene, c-kit. As the maturation of erythroid cells is coupled with gradual chromosome condensation and repression of genes involved in proliferation, we predict that MTB coordinates these processes, in part through its association with SCL and E12.
Materials and methods

Cloning of full-length Mtb
The N-terminal sequences of MTB were polymerase chain reaction (PCR) amplified from a murine fibroblast cDNA library using Klentaq-LA Polymerase (Clontech, Mountain View, CA, USA). The PCR product was then inserted in-frame into the 5 0 end of the original MTB construct to generate the new MTB full-length cDNA.
Mammalian expression plasmids and constructs
Expression plasmids encoding murine SCL, E12 and FOGzf5-6 (zinc-fingers 5 and 6 of FOG) were previously described. 16, 17 The Myc-tagged or the Flag-tagged MTB constructs were generated by subcloning the relevant portions of MTB cDNA into the pEF1/Myc-HisB vector (Invitrogen, Carlsbad, CA, USA), or the Flag-epitope vector. 18 The N and C-terminal MTB-green fluorescent protein (GFP) fusion constructs were generated by subcloning the EGFP cassette into the Flag-MTB vector, between the Flag-epitope and MTB coding sequence or after the MTB coding region, respectively.
Immunoprecipitations and Western blot analysis
Expression constructs were transfected into COS cells using either FuGene 6 reagent (Roche, Indianapolis, IN, USA) or polyfect (Qiagen, Valencia, CA, USA). Nuclear and cytoplasmic extracts were prepared as described. 17 Immunoprecipitations were performed with either an anti-Flag antibody (Stratagene, La Jolla, CA, USA) or an anti-myc antibody (9E10, Santa Cruz Biotechnology, Santa Cruz, CA, USA). E12 was detected with anti-E12 antibody (H-208, Santa Cruz) whereas SCL was detected with an anti-SCL antibody. 16 Immunofluorescence COS cells grown on cover slips were transfected with the MTB-EGFP fusion constructs alone or cotransfected with SCL, E12 or Flag-FOGzf5-6 expression vectors using Polyfect reagent. At 24 h after transfection, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline for 10 min, permeabilized in 0.5% Triton X-100 and stained with anti-SCL, anti-E12 or antiFlag antibodies, followed by TRITC-conjugated secondary antibodies. The stained cover slips were then mounted with Vectashield containing DAPI (Vector Laboratories, Burlingame, CA, USA). Fluorescence was detected using a Zeiss Axioplan microscope.
Yeast repression assays
Yeast repression was assayed using a system previously described. 19 A gene encoding a fusion protein between yeast Gal4p (amino acids 1-147 representing the DNA-binding domain) and MTB was created and introduced into yeast on an ARS-CEN vector, in which expression of this gene is under the control of the ADH1 promoter. To quantitate levels of repression, the reporter plasmid 17CLU (derivative of pRS314-17d80lacZdNeo) was introduced. 19, 20 Units of activity were calculated from ((A450 Â 1000)/(A595 Â time in min)). Results are presented as percent activity.
Reporter assays NIH3T3 cells cultured in Dulbecco's modified Eagle's medium low glucose with 10% fetal bovine serum were transfected with expression vectors using the Polyfect reagent. At 48 h after transfection, cells were collected, lysed and assayed for luciferase activity using luciferase assay kit (Promega, Madison, WI, USA). A pSV-bgal plasmid (Promega) was included as the internal control and b-galactosidase activity was measured using standard protocols. 21 Quantitative reverse transcriptase-polymerase chain reaction Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse-transcribed using oligo (dT) and SuperScript III reverse transcriptase (Invitrogen). Real time-PCR was performed as previously described and analyzed by the DC t method. 22 Values were normalized to glyceraldehyde-3-phosphate dehydrogenase. Primer sequences are available upon request.
MTB overexpression in murine erythroleukemia cells and differentiation assay
Full-length and deletion mutants of MTB were cloned into the MIGR1 retroviral vector, upstream of the IRES-GFP cassette. Retroviral particles were generated via transient transfection of FNX packaging cells with the above constructs. Murine erythroleukemia cells were infected by spinoculation on two consecutive days as previously described. 22 Erythroid differentiation was induced with 2% dimethyl sulfoxide (DMSO) and assessed by benzidine staining.
Results
MTB is the murine homolog of hCAP-G2
MTB was initially isolated from a MEL cell library by a yeast two-hybrid screen designed to identify novel SCL-interacting proteins. 10 The Mtb fragment obtained from the yeast twohybrid screen encodes the 211 amino acid C-terminal domain of the protein, which we named AD4 fragment. A longer version of the MTB cDNA, which encodes a protein of 631 amino acids, was cloned from a phage MEL cell library. This murine cDNA was homologous to a predicted human gene named FLJ20311, which was later identified as the CAP-G2 subunit of condensin II complex, 1 but had a longer N-terminal extension in comparison to MTB. We designed primers based on the GenBank sequence and isolated the missing 5 0 end of MTB by PCR using a murine fibroblast cDNA library as template. The PCR product was then cloned in-frame into the 5 0 end of the original MTB construct. The complete Mtb 7.5 kb cDNA encodes a protein of 1138 amino acids that is highly homologous to hCAP-G2 at both the DNA (84% identity) and protein (80% identity) levels ( Figure 1 ). hCAP-G2 is not related to any other murine transcript in the database, further supporting the conclusion that MTB is the murine homolog of hCAP-G2. Both MTB and hCAP-G2 contain five huntingtin, elongation factor 3, protein phosphatase 2A and TOR1 (HEAT) repeats and two leucine zipper motifs (Figure 1 ), which are involved in protein-protein interactions. The original 631 amino-acid fragment we isolated from the phage library was named D507 and the AD4 fragment was renamed D927.
MTB interacts with SCL and E12 in mammalian cells
To identify the region within SCL that interacts with MTB, we performed standard yeast two-hybrid assays with various SCL deletion constructs. The D927 fragment of MTB strongly interacts with the bHLH domain of SCL, which is both necessary and sufficient for interaction with MTB ( Figure 2a) . Next, to confirm that MTB interacts with SCL in mammalian cells, we cotransfected Flag-tagged MTB D927 along with SCL into COS cells and immunoprecipitated proteins using an anti-Flag antibody. Western blot analysis confirmed that SCL was coimmunoprecipitated from extracts by the Flag-tagged D927 (Figure 2b , lane 5). We also tested whether MTB could interact with two other bHLH proteins: the class A protein E12 and the muscle-specific transcription factor myogenin. We found that Stem cell leukemia can promote the nuclear localization of MTB We next investigated whether MTB localizes to the nucleus, similar to hCAP-G2. 1, 23, 24 We generated two different MTB-EGFP fusion constructs, linking the EGFP cassette to either the 5 0 or the 3 0 end of full-length MTB protein, and transfected both constructs into COS cells to visualize the cellular localization of MTB protein. Surprisingly, we observed that both EGFP-MTB and MTB-EGFP were largely restricted to the cytoplasm (Figure 2d , i-ii, and data not shown). This result contradicted previous findings that human condensin II complex localizes in the nucleus throughout the cell cycle. 23, 24 To investigate whether MTB nuclear localization may be dependent on a limiting cofactor, we asked whether co-transfection of SCL or E12 would affect its localization. Indeed, the localization of MTB changed in the presence of ectopically expressed SCL (Figure 2d, iii-v) . Furthermore, we observed nuclear expression of MTB-EGFP when E12 was ectopically expressed (Figure 2d , vi-viii). In contrast, overexpression of Flag-FOG, which does not bind MTB, did not affect the localization of MTB-EGFP (Figure 2d , ix-xi).
MTB is a transcriptional repressor when expressed in yeast
To determine whether MTB could influence transcription, we first performed one-hybrid experiments in yeast. The MTB D507 clone was fused to the Gal4 DNA-binding domain (Gal4DB) and introduced into yeast harboring a Gal4-driven reporter gene. In the presence of Gal4DB-MTB (DB-MTB), but not Gal4DB alone (DB), expression of the b-galactosidase reporter gene was reduced approximately three-fold (Figure 3a , Po0.0003), similar to the repression mediated in this same system by the retinoblastoma (pRB) protein. 19 MTB also repressed the expression of a histidine reporter, as evidenced by the failure of MTB-expressing cells to form colonies on media lacking histidine with 10 mM 3-AT (Figure 3b , cf. streaks 1 and . To test which corepressors might be required for the repression activity of MTB, we introduced the Gal4DB fusion protein into a set of otherwise isogenic yeast strains harboring deletions of known yeast transcription factors. We found that MTB-dependent repression was abrogated in strains lacking either SIN3 or RPD3 (Figure 3b and c) , which are the orthologues of mammalian class I histone deacetylases. Another uncharacterized mutation, R25, which has been shown to block the repression of a number of factors that recruit Rpd3P (BK Kennedy, unpublished observations), also interfered with repression by MTB. Thus, MTB can function as a transcriptional repressor in yeast, likely by recruiting histone deacetylases.
MTB represses E12-mediated transactivation in mammalian cells
We next examined whether MTB could antagonize the transcriptional activation of SCL and E12 in mammalian cells. Transfection of 3T3 cells with the E1bLUC-E6 reporter, which harbors six copies of the preferred E12/SCL binding sequence, 13 and an E12 expression vector resulted in high levels of luciferase expression. Co-expression of the full-length MTB, MTB D507 or MTB D927, all inhibited the luciferase activity induced by E12 in a dose-dependent manner (Figure 4a and b) . Of note, the strongest repression activity was mediated by full-length MTB (Figure 4b ), which suggested that while the C-terminal domain of MTB is sufficient to repress E12-mediated transactivation, the N-terminal half of the protein contains an additional repression domain. To investigate whether MTB represses E12-mediated transcriptional activation by recruitment of histone deacetylases, we performed the reporter assays in the presence of the histone deacetylase inhibitor Trichostatin A (TSA). As shown in Figure 4c , the addition of 50 nM TSA dramatically alleviated the repression by MTB D507, and restored the transactivation by E12 to baseline levels. Interestingly, the repression activity of full-length MTB was not diminished by the addition of TSA (Figure 4c ). These results suggest that MTB harbors at least two MTB/mCAP-G2 promotes erythroid cell differentiation Y Xu et al repression motifs that function via different pathways: a TSA sensitive one located at the C-terminus, which mediates the recruitment of mSin3A and associated HDACs, and a TSA resistant one in the N-terminal region.
MTB is highly expressed in erythroid cells
To investigate the role of MTB in erythroid cells, we first compared the expression level of MTB in hematopoietic versus nonhematopoietic cell lines. Quantitative real-time RT-PCR (qRT-PCR) revealed that the expression of MTB in MEL cells was 14-fold higher than that detected in NIH3T3 cells, whereas the murine megakaryocytic cell line Y10 expressed fivefold higher than that of NIH3T3 cells (Figure 5a ). Northern blot analysis confirmed that MEL cells expressed higher levels of MTB than 3T3 cells (data not shown). In contrast, expression of MTB in CJ7 ES cells was only about 2.5-fold higher than that of NIH3T3 cells. We next examined the expression levels of other condensin genes. The condensin II subunit mCAP-D3 exhibited similar expression levels as MTB in these cell lines, whereas the condensin I subunit mCAP-G, and the common component of both condensin complexes, mSMC2, are expressed at higher levels than MTB in all four cell lines examined (Figure 5a ). Therefore, although condensin complexes are ubiquitously expressed in dividing cells, the levels vary in different cell types, with a strikingly higher expression level in hematopoietic cells. We next examined how MTB expression changes during erythroid cell differentiation. Murine erythroleukemia cells were induced to undergo erythroid differentiation, and total RNA was isolated at 24, 48, 72 and 96 h after induction. Quantitative realtime RT-PCR showed that there was a transient upregulation of MTB at 48 h of differentiation, and that this level was maintained up to 96 h after induction, a time when cells are undergoing maximum maturation and expressing high levels of b-major globin (Figure 5b ). We also examined MTB expression in cultured human erythroid cells at various stages of maturation. 25 Total RNA was extracted from cells after 3, 7, 9 and 13 days of culture, and qRT-PCR was performed to examine the expression levels of MTB. As shown in Figure 5c , MTB is upregulated after day 7 of culture, when nuclear condensation is initiated. MTB expression level continues to increase up to day 13 of culture, when the majority of cells are orthochromatic and beginning to undergo enucleation. The upregulation of MTB expression therefore appears to coincide with the chromatin structure changes during erythroid differentiation.
Overexpression of MTB promotes murine erythroleukemia cell differentiation
To investigate the role of MTB during erythroid differentiation, we overexpressed MTB in MEL cells. Murine erythroleukemia cells were infected with retroviruses harboring full-length MTB-IRES-GFP, MTB D927-IRES-GFP or the empty GFP vector. Following infection, GFP þ cells isolated by fluorescenceactivated cell sorter were expanded and then induced to differentiate by the addition of DMSO. Overexpression of MTB in the GFP (Figure 6a and c) . In contrast, overexpression of MTB D927 did not lead to any change in differentiation despite high levels of expression (Figure 6a-c) . In addition, MTB did not induce MEL cell differentiation in the absence of DMSO (data not shown). These results demonstrate that overexpression of full-length MTB facilitates the maturation of erythroid cells, and that the C-terminal SCL interaction domain is not sufficient to promote erythroid differentiation.
MTB represses c-kit expression
During erythroid differentiation, genes involved in erythroid function are upregulated, whereas many other genes are downregulated. The latter set of genes includes GATA-2, MTB/mCAP-G2 promotes erythroid cell differentiation Y Xu et al c-myc and the SCL target gene, c-kit, which encodes the transmembrane receptor for kit ligand. c-kit expression is essential for stimulating early hematopoietic proliferation, but its expression level drops precipitously in maturing erythroid cells. Stem cell leukemia has been implicated in controlling c-kit expression as a member of a large multi protein complex that also includes E12, LMO2, Ldb1 and GATA-1. 11 As MTB repressed SCL/E12-mediated transcriptional activation, we assayed whether MTB could repress the expression of this SCL/E12 target gene. We transfected NIH3T3 cells with a luciferase reporter harboring a portion of the c-kit promoter, 26 along with SCL and E12, and then assayed for luciferase expression in the presence and absence of MTB. Both full-length MTB and MTB D507 resulted in a decrease in the expression of this reporter in a dose-dependent manner (Figure 7a ), whereas MTB D927 failed to repress transactivation of the c-kit reporter (data not shown). Next, we investigated whether downregulation of c-kit was more pronounced in cells that overexpressed MTB. As expected, the expression of c-kit, c-myc and GATA-2 were downregulated upon differentiation (data not shown). However, the expression of c-kit was repressed to a much greater extent in MEL cells that overexpressed MTB (Figure 7b ) compared to those cells only expressing GFP. These results are consistent with the model that MTB promotes erythroid differentiation likely through the downregulation of SCL target gene c-kit.
Discussion
The protein sequence of MTB shares 80% identity and 89% similarity with hCAP-G2, suggesting that MTB is very likely the murine counterpart of the CAP-G2 subunit of the condensin II complex. However, due to the lack of anti-MTB antibody, we have not confirmed that MTB exists in the murine condensin II complex. The two condensin complexes display non-redundant functions during mitosis, and are differentially localized to the metaphase chromosomes. 1, 23, 24 It is worth noting that only condensin II is located within the nucleus during interphase, 1 which suggests that condensin II subunits might be responsible for the nonmitotic functions such as gene repression and checkpoint control during interphase. It is also likely that other cofactors cooperate with condensin II subunits for these functions. In our studies, MTB interacts with SCL and E12 and plays a role in gene repression and erythroid differentiation.
Recently, it has been demonstrated that SCL interacts with pericentromeric chromatin to repress transcription through a chromatin remodeling mechanism that involves histone H3 lysine 9 methylation and heterochromatin protein HP1 binding. 27 It is possible that MTB is also involved in this chromatin remodeling and transcriptional repression, which might be important for maintaining the long-term culture initiating cell potential in early hematopoietic progenitor cells. Owing to the lack of a suitable anti-MTB antibody, we have not been able to confirm that MTB interacts with SCL or E12 in hematopoietic cells. However, based on the interaction and colocalization studies and transcriptional reporter assays presented here, we believe that MTB and SCL interact at least transiently during erythroid cell maturation.
The later stages of erythropoiesis involve nuclear chromatin condensation and reduction of the size of nucleus. Accompanying the alterations in chromatin higher-order folding and nuclear shrinkage, DNA replication and RNA transcription are largely inactivated. Although the mechanism by which MTB functions during erythroid differentiation is unclear, we envision two intriguing possibilities. First, MTB may regulate chromosome condensation during erythroid maturation. Overexpression of MTB, therefore, may facilitate condensation and promote terminal maturation of cells that have been triggered to undergo differentiation. Alternatively, MTB may be required for repression of genes that need to be downregulated during terminal differentiation. This latter activity of MTB may function specifically through the interaction with SCL and E12, or affect gene expression globally. These two hypotheses are not mutually exclusive, as both chromosome condensation and gene repression are observed during erythroid cell differentiation. MTB/mCAP-G2 promotes erythroid cell differentiation Y Xu et al
